|Day Low/High||0.51 / 0.53|
|52 Wk Low/High||1.84 / 8.95|
First Phase 3 Trial for Treatment of Military-Related Posttraumatic Stress Disorder (PTSD) Planned to Begin in First Quarter 2017
New Results to be Presented in Poster Session at International Society for Traumatic Stress Studies 32nd Annual Meeting
These stocks are ready to break out and trade higher from current levels. Here's how to trade them from here.
Key Opinion Leader (KOL) & Investor Event on October 26th
First Pivotal Phase 3 Study of TNX-102 SL to Report Topline This Quarter